Galera Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRTX research report →
Companywww.galeratx.com
Galera Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy.
- CEO
- J. Mel Sorensen
- IPO
- 2019
- Employees
- 3
- HQ
- Malvern, PA, US
Price Chart
Valuation
- Market Cap
- $7.67M
- P/E
- 0.07
- P/S
- 0.00
- P/B
- 1.98
- EV/EBITDA
- -0.38
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -210.64%
- ROIC
- -114.15%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $149.05M · 886.25%
- EPS
- $1.51 · 531.43%
- Op Income
- $-6,042,000
- FCF YoY
- 50.19%
Performance & Tape
- 52W High
- $0.15
- 52W Low
- $0.01
- 50D MA
- $0.07
- 200D MA
- $0.04
- Beta
- 2.64
- Avg Volume
- 309.71K
Get TickerSpark's AI analysis on GRTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 7, 26 | Emerald Bioventures, LLC | other | 0 |
| Apr 7, 26 | Emerald Bioventures, LLC | other | 20,813,818.6 |
| Apr 7, 26 | FRIEDMAN MICHAEL R. | other | 5,336,870 |
| Apr 7, 26 | FRIEDMAN MICHAEL R. | other | 5,336.87 |
| Apr 7, 26 | CHANG NANCY T | other | 1,180,611 |
| Apr 7, 26 | CHANG NANCY T | other | 1,180.611 |
| Nov 20, 25 | Sorensen Mel | sell | 70,000 |
| May 1, 25 | Sussman Joel F. | other | 2,000,000 |
| May 1, 25 | Sorensen Mel | other | 6,000,000 |
| Feb 24, 25 | LOKAY KEVIN G | other | 48,000 |
Our GRTX Coverage
We haven't published any research on GRTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GRTX Report →